



6th World Congress on

Targeting Microbiota

Towards Clinical Revolution

October 28-30, 2018 - Porto, Portugal

Congress Sessions:

- Microbiota 2018: recent advances & challenges
- Recent analysis, methods, bioinformatics & interpretations
- Strategic role of metabolites and mediators on the microbiota-host cross-talk
- Strategies to manipulate microbiota & medicine of tomorrow

Call for Abstracts

Fri. Short Oral Submission
Sept. 28, 2018

Fri. Poster Submission
Oct. 5, 2018

Register & Save before

Wed. Registration
Oct. 2, 2018

Microbiota 2018 Speakers



Recent advances on gut microbiota and food intolerances

Yurdagül Zopf
University of Erlangen-Nuremberg, Germany



Psycho neuro immunology and gut microbes

Paul Forsythe
McMaster University, Canada



Targeted gut microbiota and short chain fatty acid profile among term and preterm infants

Jan Mazela
Poznan University of Medical Sciences, Poland



Honor thy lodgers? Interactions between the built environment microbiome and the human microbiome

Markus Egert
Furtwangen University, Germany



Phage therapy strategy to modulate the child stunting microbiota

Mohammadali Khan Mirzaei
McGill University, Canada



Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes

Julien Diana
Inserm, France



Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases

Maria Cecilia Giron
University of Padova, Italy



Exploring the role of gut dysbiosis in neuroinflammation and hypertension

David Durgan
Baylor College of Medicine, USA



Impact of antibiotic treatment on the human microbiota - a review of the clinical implications

Maria Vehreschild
University Hospital of Cologne, Germany



Role of microbes in stem cells transplantation related complication

Ernst Holler
University Hospital Regensburg, Germany



MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response

Antonio Riva
Institute of Hepatology London, United Kingdom



The effect of gut bacterial metabolites on cardiovascular risk

Marcin Ufnal
Medical University of Warsaw, Poland



Using germfree animal models to prove the role of the gut microbiota in liver diseases

Philippe Gérard
Inra, France



Link between microbiota & visceral pain: role of bioactive lipids

Cenac Nicolas
Inserm, France